These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17705040)

  • 21. [Widespread argentophilic structures in progressive supranuclear palsy--an autopsy case report].
    Hanihara T; Kubota H; Amano N; Yamaoka K; Yagishita S
    No To Shinkei; 1994 May; 46(5):487-92. PubMed ID: 8060688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
    Ferrer I; Blanco R; Carmona M; Puig B
    J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An autopsied case of progressive supranuclear palsy presenting with cerebellar ataxia and severe cerebellar involvement.
    Iwasaki Y; Mori K; Ito M; Tatsumi S; Mimuro M; Yoshida M
    Neuropathology; 2013 Oct; 33(5):561-7. PubMed ID: 23320789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression and activity of antioxidants in the brain in progressive supranuclear palsy.
    Cantuti-Castelvetri I; Keller-McGandy CE; Albers DS; Beal MF; Vonsattel JP; Standaert DG; Augood SJ
    Brain Res; 2002 Mar; 930(1-2):170-81. PubMed ID: 11879807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lewy bodies in progressive supranuclear palsy represent an independent disease process.
    Uchikado H; DelleDonne A; Ahmed Z; Dickson DW
    J Neuropathol Exp Neurol; 2006 Apr; 65(4):387-95. PubMed ID: 16691119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebellar cortical tau pathology in progressive supranuclear palsy and corticobasal degeneration.
    Piao YS; Hayashi S; Wakabayashi K; Kakita A; Aida I; Yamada M; Takahashi H
    Acta Neuropathol; 2002 May; 103(5):469-74. PubMed ID: 11935262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant accumulation of ErbB4 in progressive supranuclear palsy.
    Murakami A; Nakamura M; Kaneko S; Lin WL; Dickson DW; Kusaka H
    Neuropathol Appl Neurobiol; 2018 Oct; 44(6):563-573. PubMed ID: 29319907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between histopathological features of progressive supranuclear palsy and disease duration.
    Josephs KA; Mandrekar JN; Dickson DW
    Parkinsonism Relat Disord; 2006 Mar; 12(2):109-12. PubMed ID: 16337422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aging and oxidative stress in progressive supranuclear palsy.
    Aoyama K; Matsubara K; Kobayashi S
    Eur J Neurol; 2006 Jan; 13(1):89-92. PubMed ID: 16420399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases.
    Armstrong RA; Lantos PL; Cairns NJ
    J Neural Transm (Vienna); 2007; 114(12):1569-77. PubMed ID: 17680229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy.
    Lorenzl S; Albers DS; Chirichigno JW; Augood SJ; Beal MF
    J Neurol Sci; 2004 Mar; 218(1-2):39-45. PubMed ID: 14759631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
    Halliday GM; Macdonald V; Henderson JM
    Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome.
    Tsuboi Y; Josephs KA; Boeve BF; Litvan I; Caselli RJ; Caviness JN; Uitti RJ; Bott AD; Dickson DW
    Mov Disord; 2005 Aug; 20(8):982-8. PubMed ID: 15834857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoperoxidation is selectively involved in progressive supranuclear palsy.
    Odetti P; Garibaldi S; Norese R; Angelini G; Marinelli L; Valentini S; Menini S; Traverso N; Zaccheo D; Siedlak S; Perry G; Smith MA; Tabaton M
    J Neuropathol Exp Neurol; 2000 May; 59(5):393-7. PubMed ID: 10888369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.
    Josephs KA; Boeve BF; Duffy JR; Smith GE; Knopman DS; Parisi JE; Petersen RC; Dickson DW
    Neurocase; 2005 Aug; 11(4):283-96. PubMed ID: 16093229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropathology of variants of progressive supranuclear palsy.
    Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
    Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.
    Albers DS; Augood SJ; Martin DM; Standaert DG; Vonsattel JP; Beal MF
    J Neurochem; 1999 Aug; 73(2):881-4. PubMed ID: 10428088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multireceptor fingerprints in progressive supranuclear palsy.
    Chiu WZ; Donker Kaat L; Boon AJW; Kamphorst W; Schleicher A; Zilles K; van Swieten JC; Palomero-Gallagher N
    Alzheimers Res Ther; 2017 Apr; 9(1):28. PubMed ID: 28412965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease.
    Freixes M; Rodríguez A; Dalfó E; Ferrer I
    Neurobiol Aging; 2006 Dec; 27(12):1807-15. PubMed ID: 16310893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
    Jellinger KA
    Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.